Virtual Library

Start Your Search

L. Zhang



Author of

  • +

    P1.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 206)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Advanced Diseases - NSCLC
    • Presentations: 1
    • +

      P1.01-006 - Targeted Drug Selection for Advanced NSCLC Treatment (ID 389)

      09:30 - 09:30  |  Author(s): L. Zhang

      • Abstract
      • Slides

      Background:
      The efficacy of traditional cytotoxic drugs that treat the Advanced Non-Small Cell Lung Cancer (ANSCLC) has reached a plateau. Recently, the targeted therapy has become a new option for ANSCLC treatment. The most representative targeted therapy is tyrosine kinase inhibitor (TKI) aimed at the genetic mutations of epidermal growth factor (EGFR). Currently, three TKI drugs, namely Gefitinib, Erlotinib, and Icotinib, are available in Chinese market. This article compared the molecular structure,pharmacokinetic parameters, clinical data, adverse reactions, and contraindications of the three drugs to guide the optimal selection in clinical practice.

      Methods:
      Not Applicable.

      Results:
      Not Applicable.

      Conclusion:
      Presently the pros and cons of the three drugs are inconclusive. Taken together, TKI can be used as the first-line drug among patients with EGFR mutations. Of these TKIs, Gefitinib is convenient and safe with fair tolerability, and consequently recommended. Icotinib needs to be administered t.i.d without meal. However, in ICOGEN study, it was safer than Gefitinib, and therefore also recommended. Erlotinib needs to be taken without meal, requires quitting smoke and has narrow therapeutic windows. The occurrence rate and severity of its adverse reactions are relatively high. Therefore Erlotinib is not recommended. Among the non-selective patients, TKI can be used as the second- or third-line treatment. Erlotinib apparently has better survival benefit and therefore is recommended. Icotinib has certain efficacy among the Acian female non-smokers with adenocarcinoma or lung adenocarcinoma. Its safety and tolerability are the best. Therefore, Icotinib is the next recommended drug. Gefitinib only has certain efficacies among the Asian female nonsmoking lung adenocarcinoma patients, and therefore is recommended to only the appropriate population.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 207)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Advanced Diseases - NSCLC
    • Presentations: 1
    • +

      P2.01-005 - Relationship between Icotinib Exposure and Clinical Outcome in Chinese ANSCLC (ID 370)

      09:30 - 09:30  |  Author(s): L. Zhang

      • Abstract
      • Slides

      Background:
      The icotinib hydrochloride tablets (Conmana) is a novel orally administered EGFR-TKI agent, which is the first homegrown anticancer drug designed, synthesizedand screened by Betapharma (Zhejiang, China) . The preclinical animal experiments showed that the agent had an anticancer activity in vitro and in vivo whose mechanism is that icotinib can inhibit EGFR activity specifically and competitively through binding to the tyrosine of the EGFR. A head-to-head Phase III clinical trial (ICOGEN) comparing the roles of icotinib and gefitinib in treating NSCLC in China has suggested that icotinib has similar (and even better) efficacy with gefitinib in treating Chinese NSCLC patients, with much better safety profiles; furthermore, it is superior to gefitinib in terms of treatment cost. Recently, a retrospective study demostrated that icotinib is active in the treatment of patients with NSCLC both in first or second/third line. Up to date, Icotinib has completed phase I、 II and III trials, Pharmacokinetic study in Phase I clinical trial data displayde that non-linear character with saturated absorption and first-order elimination. But whether the exposure of icotinib would influence the therapeutic effects is cofused us.So Beta Pharma (China) and Peking Union Medical College Hospital (PUMCH) jointly conducted this single-center open-label Phase I clinical trial, from August 2007 to April 2009, to explore the relationship between icotinib exposure and clinical outcomes of a single dose or administration for 31 consecutive days among Chinese NSCLC patients. In this article, by analysing the clinical efficacies and pharmacokinetic characteristics of iconitib in 30 subjects, we tried to elucidate the relationship between the iconitib exposure and therapeutic effects.

      Methods:
      In this single-center open-label phase I clinical trial, a dose-escalation method was applied until disease progression or unacceptable toxicities. Different doses of icotinib were orally administered for 31 consecutive days in different groups until disease progression or unacceptable toxicities. Blood samples were collected in the first treatment cycle (day 1 - day 28) for the pharmacokinetic analysis. Tumor responses were assessed by using the Response Evaluation Criteria in Solid Tumors(RECIST). The plasma concentrations of icotinib were assessed by liquid chromatography–mass spectrometry (LC-MS).

      Results:
      Univariate analysis showed that the time to maximum (Tmax) after a single dose of icotinib was significantly correlated with the overall survival (OS) (Spearman correlation coefficient=0.441, P=0.021). Patients with higher Clast were independently associated with PFS (p=0.012). Multivariate analysis showed that the AUC0-last and AUC0-∞ after a single dose of icotinib were significantly correlated with OS (P=0.037, P=0.042, respectively).. Stratification of these subjects according to smoking status indicated significant correlation between OS and AUC0-last (Spearman correlation coefficient = -0.709, P=0.015).

      Conclusion:
      Iconitib is a novel EGFR TKI developed by Chinese scientists. For advanced NSCLC patients who have failed prior treatment(s), the exposure of a single dose of iconitib was significantly correlated with the treatment efficacy. This finding may provide a simple and feasible clinical indicator for predicting the survivals.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.